Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 10 of 10 for “"riluzole"”.
-
Model-Informed Drug Development of Riluzole for Neuroprotection in Acute Spinal Cord Injury: Integrating Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes for Precision Medicine
… and a relatively small patient population. Riluzole, a sodium channel blocker with established neuroprotective properties, was evaluated in the Riluzole in Spinal Cord Injury Study (RISCIS), a Phase II/III clinical trial conducted by the North American Clinical Trials Network (NACTN). This …
-
Investigation of Riluzole’s Synaptic Protection Mechanism Through HSF1-BDNF Axis
… amyotrophic lateral sclerosis (ALS) drug Riluzole has great potential in treating Alzheimer’s disease (AD) based on promising animal data as well as its known action on modulating synaptic transmission. However, its detailed mechanism of action is not fully understood. Here, we proposed …
-
Novel Use of Dual Anti-Inflammatory Therapy to Overcome Drug Resistance and Improve Functional Recovery Following Spinal Cord Injury
… spinal cord uptake of systemically-delivered riluzole, a drug that is currently being evaluated in clinical trials as an SCI intervention. Blood-to-spinal cord riluzole penetration was reduced following SCI in wild-type but not Pgp-null rats, highlighting a critical role for Pgp in mediating …
-
Amyotrophic Lateral Sclerosis: mechanism behind mutant SOD toxicity and improving current therapeutic strategies
… production of survival factors by glial cells. Riluzole is the only FDA approved drug for the treatment of ALS and it shows a small but significant increase in patient lifespan. Our results show that acute riluzole treatment stimulated trophic factor production by astrocytes and Schwann cells. …
-
Targeting ALS: A Multi-Cellular Study on the Potential Therapeutic Role of Azole-Based Compounds
… of azolium-based compounds, focusing on Riluzole, one of the two FDA-approved drugs for ALS treatment. While riluzole blocks glutamate release to slow disease progression, it does not significantly extend patient survival or alleviate symptoms. There is limited understanding of how …
-
The role of apoptosis in <i>in vitro</i> and <i>in vivo</i> models of amyotrophic lateral sclerosis
… agent (EPO) were ineffective, while riluzole showed protective effects. <br></br><br></br>Although alternative cell death pathways should be investigated, my study excludes apoptosis as the mechanism of death in cervical motor neurons of wobbler mice.
-
Distinct functional effects of NMDA receptors in normal and leukaemic megakaryocytes
… NMDAR antagonists (memantine, MK-801, AP5 and riluzole) and agonists (glutamate and NMDA). Cells from patients with megakaryocytic cancers were also used to confirm NMDAR expression. The second part of this thesis used normal mouse megakaryocytes in primary cultures to examine NMDAR …
-
Investigating the role of mitochondrial dysfunction in a Drosophila model of C9orf72 ALS/FTD
… however, only one globally licensed treatment (Riluzole) is available which only prolongs survival by a modest 2–3 months. A hexanucleotide repeat expansion consisting of GGGGCC (G4C2) in the first intron of C9orf72 is the most common pathogenic mutation in ALS/FTD. Three disease mechanisms have …
-
Die Modulation der Glutamatfreisetzung - ein Ansatz der neuroprotektiven Pharmakotherapie
Glutamat ist der bedeutendste erregende Transmitter des zentralen Nervensystems. Ein wichtiger pathophysiologischer Mechanismus bei Schädigungen von Nervenzellen ist hingegen die Exzitotoxizität, d.h. die toxische Wirkung von Glutamat durch exzessive Stimulierung seiner Rezeptoren. Diesbezüglich …
-
Inhibition of cellular glutamate efflux as a novel strategy to curb canine hemangiosarcoma proliferation and survival
Submission published under a 24 month embargo labeled 'U of I Access', the embargo will last until 2026-05-01